Genetic Testing à la Myriad
March 2012. Myriad Genetics’ offerings are contentious, in particularly when it comes to patent protection of genes – once in Europe, now in the U.S. In the exclusive interview with B2Bioworld, Peter Meldrum, CEO and co-founder of the Utah-based company describes expansion plans with biomarker services. He takes a stand on clinical DNA chips, and answers reproaches of patenting human genes, blocking scientific research, or pursuing a strangling licence policy for those laboratories willing to make breast cancer or colon carcinoma tests more widely available to patients. What will be Myriad’s future course, after Mr. Meldrum reaches retirement age.Reading time: 10 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Big Data & Research – Acquisition, Analytics, and Exploitation
Shift in Cancer Research Translation
Christof von Kalle, at the time Head of Germany’s National Center for Tumor Diseases on new approaches to achieve tangible clinical results – or to manoeuvring into dead ends
Clinical Microfluidics: Sample in – Results out?
Marc Feiglin, at the time Chief Technology Officer Life Sciences at Tecan on electrowetting technology, blood diagnostic devices and prospects of clinical microfluidics
Prospecting and Monitoring Distributors in Iran
Accessing a Resistance Economy